PARATHAR Drug Patent Profile
✉ Email this page to a colleague
When do Parathar patents expire, and when can generic versions of Parathar launch?
Parathar is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in PARATHAR is teriparatide acetate. There is one drug master file entry for this compound. Additional details are available on the teriparatide acetate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PARATHAR?
- What are the global sales for PARATHAR?
- What is Average Wholesale Price for PARATHAR?
Summary for PARATHAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| Patent Applications: | 1,801 |
| DailyMed Link: | PARATHAR at DailyMed |
US Patents and Regulatory Information for PARATHAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PARATHAR | teriparatide acetate | INJECTABLE;INJECTION | 019498-001 | Dec 23, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
